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duration of onset of bacteremia after UCBT with a median of 15
days and the duration of 3-34 days, compared with after UBMT.
Graft-vs-host disease of grade II, III or IV occurred in 2 of 10
patients who survived more than 100 days after UCBT and in 15
of 40 after UBMT. The TRM and EFS at 2 years post-transplant
in patients at an early disease stage were 12.5 % and 75.0 % after
UCBT and 6.5% and 68.7% after UBMT. Conclusion: UCB
transplantation in adults is associated with delayed neutrophil re-
covery and longer duration of bacteremia at early time points after
transplantation. The TRM (12.5%) and EFS (75.0%) at 2 years
after transplantation were similar to our experience of UBMT.
Thus, parallel to the search for a matched unrelated donor, search-
ing for an adequate UCB unit should be initiated.
110
REDUCED-INTENSITY CONDITIONING IS VERY EFFECTIVE IN PATIENTS
WITH INDOLENT LYMPHOPROLIFERATIVE DISORDERS AND HAS LIM-
ITED SUCCESS IN ACUTE LYMPHOBLASTIC LEUKEMIA. EXPERIENCE IN
A SINGLE INSTITUTION IN ME´XICO
Gomez-Almagur, D., Gutierrez-Aguirre, C.H., Cantu-Rodriguez, O.G.,
Gonzalez-LLano, O., Jaime-Perez, J.C., Mancillas-Guerra, C.,
Herrera-Garza, J.L. Hospital Universitario, U.A.N.L., Monterrey,
Nuevo Leon, Mexico.
The published experience of reduced-intensity allogeneic stem
cell transplantation (ASCT) for acute lymphoblastic leukemia
(ALL) remains limited. Some studies have been shown that the
graft-versus-leukemia effect is not powerful enough to make this
conditioning regimen useful in ALL. On the other hand, indolent
lymphoproliferative disorders (ILD) has been associated, in some
studies, with high mortality when reduced-intensity ASCT was
used as a piece of a treatment. We evaluated the outcome and
survival of both ALL and ILD patients who received a reduced-
intensity SCT in our hospital. A total of 20 high risk patients in
ALL group and 10 patients in ILD group (3 with chronic lympho-
cytic leukemia and 7 with indolent non Hodgkin lymphoma) were
included. The median age for both groups was 19 years and 43
years respectively. All patients received cyclophosphamide IV 300
mg/m2and ﬂudarabine 30 mg/m2 for 3 days (6, 5, 4) and
cyclophosphamide IV 50 mg/kg/day or busulphan 4 mg/kg/day for
2 days (3, 2) as conditioning regimen. In 20 patients (67%) it
was administrated as ambulatory setting. Daily oral cyclosporine
and methotrexate (days 1, 3, 5) were delivery as prophylactic
GVHD. The median CD34 cell dose infused was 5.37  106 in
ALL and 5.2  106 in ILD group. Neutrophil recovery to 0.5 
109/l was observed at day 13 (median) in both groups. Acute and
chronic GVHD was developed more frequently in ILD group than
in ALL group (40% vs. 25%). Relapse was higher in ALL group
(65%) than in ILD group (10%) and this complication was the
principal cause of death in both groups (50% vs. 10%). In all, 19
patients died, 16 (80%) patients in ALL group and 3 (30%) pa-
tients in ILD group. We conclude that reduced-intensity ASCT in
high-risk ALL patients could not be the best choice for treatment.
We believe that this conditioning regimen can be used successfully
in treatment of patients with ILD, however, in ALL more studies
and new ideas are needed.
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REDUCED INTENSITY CONDITIONING (RIC) FOR ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION (HCT) IN PATIENTS WITH
AML EVOLVED FROM MDS OR THERAPY RELATED AML
O’Donnell, M.R., Roberto, R., Stein, A.S., Palmer, J., Slovak, M.,
Nakamura, R., Snyder, D.S., Chang, K., Pullarkat, V., Forman, S.J.
City of Hope Comprehensive.
Between 1/1/2000 and 12/31/2004, 22 patients (pts) with either
AML with antecedent MDS (18 pts) or therapy related AML (4
pts) received (RIC) for allogeneic HCT from either HLA matched
sibling or unrelated donor (MRD) (11 pts each). The median age
was 60.5 yrs (range 30-71). The majority of patients were in
remission (CR  12, CR2  2) but 8 pts had active disease (3
induction failure, 3 relapse and 2 untreated); marrow blasts in this
group ranged from 8% to 80% with 10% circulating blasts at
HCT in all but one. Cytogenetic risk groups were unfavorable (8),
intermediate (13) and favorable (1). Fludarabine (FLU) and mel-
phalan (Mel) was the (RIC) 19 pts; FLU and TBI 200 cGy in 2 pts
and FLU/BU, in 1 pt GVHD prophylaxis was CSP MMF in 10
pts, CSA MMF MTX in 11 pts, and FK 506 MTX in 1 pt.
Stem cell source was PBSC in 21. Median time to WBC 	500 was
15 days (6-27) and plts 	20000 was 18 days (1-32 d). Grade 2-4
acute GVHD occurred in 12 pts (54%) while 15 pts (67%) at risk
developed chronic GVHD. The day 100 mortality was 23%. With
a median follow up of 24 months, 11 pts are alive with 10 in
remission for an OS of 49% and a DFS of 45%. Six pts relapsed (5
sibling and 1 URD) (relapse rate, 36%). There was no signiﬁcant
difference between OS and EFS based on age, cytogenetics, remis-
sion status or donor source although there was a trend (P .06) for
relapse base on donor source. Reduced intensity conditioning of-
fers improved survival for patients with high risk AML when
compared to conventional chemotherapy. Treatment related mor-
tality is acceptable but further efforts are needed to reduce relapse
in related donors.
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REDUCED INTENSITY MATCHED RELATED (MRD) AND MATCHED UN-
RELATED (MUD) ALLOGENEIC STEM CELL TRANSPLANTATION (RIST)
IN ADULTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE
MYELOID LEUKEMIA (AML): A SINGLE CENTER EXPERIENCE
Kassim, A.A.1, Jagasia, M.H.1, Vusirikala, M.2, Dixon, S.L.1,
Chinratanalab, W.2, Morgan, D.S.1, Ruffner, K.L.1, Greer, J.P.1,
Stein, R.S.1, Goodman, S.A.2, Mineishi, S.1, Schuening, F.G.1 1.
Vanderbilt University Medical Center, Nashville, TN; 2. Veterans Ad-
ministration Medical Center, Nashville, TN.
Introduction:The median age of diagnosis in AML is more than
60 years, and adequate management of AML in older patient’s
remains controversial. Due to an increase in comorbid illnesses,
graft versus host disease (GVHD) with aging and arbitrary age
limit for allogeneic stem cell transplantation is 55 years in many
centers. RIST can potentially reduce treatment related mortality of
older patients and provides the curative potential of allogeneic cell
therapy. Methods: We analyzed the outcome of 23 consecutive
patients with AML or MDS, undergoing RIST from a MRD or
MUD. Conditioning regimen for both was ﬂudarabine (180 mg/
m2) and busulfan (PO 8 mg/kg or IV 6.4 mg/kg), plus total body
irradiation (4 Gy) for MUD. GVHD prophylaxis consisted of
cyclosporine and mycophenolate mofetil. Results: 12 patients un-
derwent a MRD and 11 had a MUD RIST. Median age at trans-
plant was 56 (range 42-67). 52% of the patients were male. Ten
patients had MDS; 12 AML and 1 myeloﬁbrosis. 16 received
peripheral blood stem cells while 7 received bone marrow trans-
plants. Median time from diagnosis to transplant was 402 days. All
patients had normal engraftment (median 17 days, platelets; 16
days, neutrophils). Survival at 100 days was 91% 1 year overall
survival is 48%, with a median follow-up of 435 days (range 53-816
days). There was no difference in survival between MRD and
MUD transplants. Three patients died of progressive disease, 1 due
to secondary malignancy and 8 from transplant related mortality.
The cumulative incidence of acute GVHD was 0 in 17%; grade I
13%; grade II 48%; III 13% and IV 9% while 2/23 had limited;
9/23 extensive chronic GVHD. Conclusion: These data suggest
that RIST is a feasible treatment option in older patients with
poor-prognosis MDS and AML. Our survival data are comparable
to similar non-myeloablative transplant approaches for these dis-
ease/age groups of patients.
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ANTIGEN SPECIFIC T-CELL RESPONSE TO ASPERGILLUS FUMIGATUS IN UN-
RELATED ALLOGENEIC TRANSPLANT RECIPIENTS
Rosenthal, H.S., Somani, J., Nolte, F.S., Waller, E.K. Emory Univer-
sity, Atlanta, GA.
Introduction: Invasive aspergillosis infection is a signiﬁcant cause
of morbidity and mortality in patients who undergo unrelated donor
allogeneic transplantation. The post transplantation period of pre-
engraftment immunosuppression is most commonly associated with
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